Tiziana announces publication of a peer reviewed article on data from the clinical trial with intranasally administered foralumab, its proprietary fully human anti-cd3 monoclonal antibody, in mild to moderate covid-19 patients in brazil
New york and london, aug. 17, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / lse: tils) ("tiziana" or the "company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces publication of a scientific article in the peer-reviewed journal frontiers in immunology titled " nasal administration of anti-cd3 monoclonal antibody (foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate covid-19 patients: a pilot study "(1). the study was completed in collaboration with scientific teams at the harvard medical school (boston, usa) and intrials, a full-service latin american cro based in sÃo paulo, brazil. the aim of the study was to assess safety of intranasal foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation in mild to moderate covid-19 patients who were outpatients at the santa casa de misericordia de santos hospital in brazil. thirty-nine patients were randomized into three cohorts: no foralumab treatment (control), nasal foralumab (100 ug) + dexamethasone (6 mg orally on days 1-3), and nasal foralumab (100 ug) alone administered for 10 consecutive days. all arms were allowed to continue standard of care medications. to view the online publication, please click here: http://journal.frontiersin.org/article/10.3389/fimmu.2021.709861/full?&utm_source=email_to_authors_&utm_medium=email&utm_content=t1_11.5e1_author&utm_campaign=email_publication&field=&journalname=frontiers_in_immunology&id=709861
TLSA Ratings Summary
TLSA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission